Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ALT-801 + Gemcitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALT-801||p53 Vaccine 5||ALT-801 is comprised of IL-2 fused to a T-cell receptor domain that targets p53, potentially enhancing immune response to p53-expressing tumor cells and resulting in increased tumor cell death (PMID: 21994418).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01625260||Phase Ib/II||ALT-801 ALT-801 + Gemcitabine||A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer||Unknown status|